Transition from phosphodiesterase-5 inhibitors (PDE5i) — such as United Therapeutics’ Adcirca (taladafil) and Pfizer‘s Revatio (sildenafil) — to Bayer‘s Adempas (riociguat), a soluble guanylate cyclase (sGC) stimulator, without a washout period is a viable option for some patients with pulmonary hypertension, a small study suggests. The…
A group of Canadian doctors highlighted the importance of an early diagnosis among those with rare diseases. The recommendation, released by the Pulmonary Hypertension Association of Canada, came out on Rare Disease Day, an international event every Feb. 28 to raise awareness of the 300 million people with rare…
A set of new genes and signaling pathways linked to the development of severe lung disease in premature infants was found by researchers from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago and collaborators. Their study, “Exome sequencing identifies gene variants and…
Inspiratory muscle weakness aggravates shortness of breath caused by exertion and lung function capacity in patients with chronic thromboembolic pulmonary hypertension, a study has found. The study, “Inspiratory muscle weakness contributes to exertional dyspnea in chronic thromboembolic pulmonary hypertension,” was published in the journal PLOS One. CTEPH is a…
Get regular updates to your inbox.